This will help the state’s largest health system to access the center’s process development and clinical manufacturing capabilities, and the center benefits by bringing on board talent from the health system.
Dr. Andrew Pecora, chief innovation officer at HMH, will be chairman of the center’s technical advisory committee.
The center provides technology and infrastructure to support cell therapy products, and training, education and workforce development solutions for cell and gene therapy companies.
Dr. Haro Hartounian, center director and NJII’s executive director, biotechnology & pharmaceutical innovation, said: “We are delighted to have HMH join the NJII Cell and Gene Therapy Development Center, and are fortunate to have an expert and pioneer like Dr. Pecora serve in the important role of chairman of the advisory committee. The center is continuing to form partnerships with leading cell and gene therapy biopharmaceutical and technology developing companies.”